Levocarnil (Levocarnitine)

Levocarnitine facilitates the transport of long‑chain fatty acids into mitochondria by forming acyl‑carnitine complexes. This enables β‑oxidation of fatty acids, producing acetyl‑CoA for the citric acid cycle and ultimately generating ATP, which helps restore normal cellular energy metabolism.

The prescribed dose of Levocarnil is determined by the treating clinician based on the patient’s age, weight, clinical condition, and laboratory values. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for levocarnitine in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant or nursing should discuss use with their healthcare provider.

To order Levocarnil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Levocarnil is an injectable levocarnitine formulation, offering rapid systemic availability compared with oral tablets or capsules, which may have variable absorption. It is suited for patients requiring immediate correction of carnitine levels, such as those with severe deficiency, dialysis dependence, or acute metabolic crises.

Levocarnil should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures. Do not freeze. Follow standard aseptic handling procedures when preparing for intramuscular or intravenous administration.

Levocarnil is supplied as an injectable solution for intramuscular or intravenous injection. Administration route, infusion rate, and volume are determined by the prescribing clinician and should be performed by qualified healthcare personnel in accordance with local practice guidelines.

The most serious adverse events include severe hypersensitivity reactions such as anaphylaxis, marked hypotension, cardiac arrhythmias, and rare seizures. Immediate medical attention is required if any of these symptoms develop during or after administration.

Levocarnil should be avoided in individuals with known hypersensitivity to levocarnitine or any excipients in the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled seizure disorders, or those receiving interacting medications listed under major interactions.